Stockreport

BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-...

BioSig Technologies, Inc.  (BSGM) 
NASDAQ:AMEX Investor Relations: biosigtech.com
PDF Westport, CT, April 24, 2020 (GLOBE NEWSWIRE) -- In vitro studies demonstrated decrease of viral production by over 98%Upon approval, clinical trial to be conducted at [Read more]